Clinical Insights
FDA Approves Klygefa (Gefurulimab) for AChR Antibody Positive Generalized Myasthenia Gravis
The US Food and Drug Administration (FDA) has approved Klygefa (gefurulimab) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. gMG is a chronic autoimmune neuromuscular disease...
FDA Approves First Treatment for Primary Membranous Nephropathy
The US Food and Drug Administration has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adults with primary membranous nephropathy (pMN) at risk of disease progression.
Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition
On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.
Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy
Positive final efficacy results from the phase 3 ORIGIN 3 trial, evaluating Trutakna (atacicept) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, discusses the findings.
More
Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles
A poster analysis of the phase 3 ADVANCE OUTCOMES trial, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that oral ralinepag reduced clinical worsening across different...
PHINDER Analysis Highlights the Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease
Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with...
FDA Approves Pimjetmi (Pimicotinib) for Patients With Tenosynovial Giant Cell Tumor
The US Food and Drug Administration (FDA) has approved Pimjetmi (pimicotinib) as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection...
UCB Study Highlights the Burden of Ocular Myasthenia Gravis
Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were...
Highlights from The Liver Meeting 2026 | The CheckRare Brief
In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics. Ultragenyx Ends Angelman Syndrome and...
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression...
Myasthenia Gravis
Myasthenia gravis (MG) is a chronic autoimmune disease that disrupts communication between nerves and muscles, causing fluctuating weakness that often worsens with activity. It can affect the...
Phase 3 OASIS Study Shows Promise of Oral Olorofim for Invasive Aspergillosis
Johan Maertens, MD, PhD, Professor of Hematology at University Hospitals Leuven (UZ Leuven) in Belgium and Principal Investigator of the OASIS study, discusses positive phase 3 trial results...
Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva (FOP)
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive...
C3G and the Pediatric VALIANT Study
C3G and the Pediatric VALIANT Study Bradley Dixon, MDBradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics,...
A Family’s Journey with Prader-Willi Syndrome
Maria Picone, co-founder and CEO of the TREND Community, and mother of a 14-year-old with Prader-Willi syndrome (PWS), discusses her family’s journey with PWS, including why more research and better...
3D Printed Treatment Options | The CheckRare Brief
In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options. New...
Molecular Changes Associated With Teprotumumab Treatment in Thyroid Eye Disease
Sarah Cheng, MD, PhD, a clinical oculoplastic fellow at the University of California, San Diego, discusses findings from an exploratory study examining the biological changes in orbital tissue...
FDA Grants Accelerated Approval to Voceryq for Recurrent Respiratory Papillomatosis
The US Food and Drug Administration (FDA) has granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce...
Mirum’s Livmarli Achieves Primary Endpoint in Phase 3 EXPAND Study
Mirum Pharmaceuticals recently announced positive topline results from its phase 3 EXPAND study, evaluating Livmarli (maralixibat) for cholestatic pruritus in patients six months and older with...
Generalized Myasthenia Gravis: AANEM 2026 Highlights
The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) held its 2026 annual meeting September 29–October 1 in Orlando. CheckRare focused its meeting coverage on generalized...
Miv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia Gravis
Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses one-year data showing sustained benefits of KYV-101 (mivocabtagene autoleucel ; Miv-cel) in stiff...
How Bispecific Antibodies Are Changing Multiple Myeloma Treatment
Nisha Joseph, MD, Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, discusses how bispecific antibodies are changing multiple...
Gambling on Clinical Trials | The CheckRare Brief
In this episode, we discuss gambling on clinical trials, the FDA approval of a new formulation of Sjögren’s disease treatment, and an approval in IgA nephropathy. FDA Approves a New...
Clinical Trials for Rare Endocrine Disorders | Rare Endocrine Exchange
In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with NIH endocrinologist Katherine Araque, MD, about clinical trials for rare endocrine disorders. The conversation examines...
Recent Videos
Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy
Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles
Interim PHINDER Analyses in Interstitial Lung Disease
Social Wall
How Sanofi is Addressing Supply Chain Issues
Sanofi’s Orphan Drug Supply Update | Special Edition
Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition
Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy
Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy
Ralinepag for Pulmonary Arterial Hypertension
Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles
Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles
CheckRare is proud to be covering #SNO2026. Stay tuned for our coverage and Expert Insights.
The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease
Interim PHINDER Analyses in Interstitial Lung Disease
New research is helping advance the understanding and treatment of rare kidney diseases.
The VALIANT study evaluated pegcetacoplan, a targeted complement therapy, in patients with C3G and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Explore the
The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease
What should you know about myasthenia gravis?
From understanding the underlying disease mechanisms to exploring FDA-approved treatment options and ongoing clinical research, staying informed is essential for the rare disease community.
The Myasthenia Gravis Disease Learning
UCB Study Highlights the Burden of Ocular Myasthenia Gravis












How Sanofi is Addressing Supply Chain Issues
CheckRare November 17, 2026 1:48 pm